BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been given an average recommendation of “Moderate Buy” by the thirteen analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $19.6364.

A number of equities analysts have recently commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, December 29th. Citizens Jmp dropped their target price on shares of BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating for the company in a research report on Wednesday, November 5th. Needham & Company LLC cut their price target on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, November 4th. Royal Bank Of Canada decreased their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Finally, Zacks Research lowered shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th.

BioCryst Pharmaceuticals Stock Up 4.6%

Shares of BCRX opened at $7.90 on Friday. BioCryst Pharmaceuticals has a fifty-two week low of $6.00 and a fifty-two week high of $11.31. The company’s fifty day moving average is $7.11 and its two-hundred day moving average is $7.40. The firm has a market cap of $1.66 billion, a PE ratio of -158.00 and a beta of 0.83.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Thursday, February 26th. The biotechnology company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $0.07 by $1.05. BioCryst Pharmaceuticals had a negative return on equity of 4.24% and a negative net margin of 1.46%.The business had revenue of $163.28 million for the quarter, compared to analyst estimates of $151.32 million. During the same period last year, the company posted ($0.13) EPS. The business’s quarterly revenue was up 209.1% on a year-over-year basis. As a group, equities research analysts anticipate that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Alane P. Barnes sold 21,773 shares of the stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $7.65, for a total value of $166,563.45. Following the completion of the sale, the insider directly owned 398,751 shares in the company, valued at approximately $3,050,445.15. This represents a 5.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders have sold 183,453 shares of company stock worth $1,330,965. 5.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Larson Financial Group LLC raised its holdings in shares of BioCryst Pharmaceuticals by 1,188.0% during the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 3,267 shares during the period. Focus Partners Wealth purchased a new position in BioCryst Pharmaceuticals in the 3rd quarter worth approximately $77,000. Mirae Asset Global Investments Co. Ltd. grew its position in BioCryst Pharmaceuticals by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 2,115 shares in the last quarter. Envestnet Portfolio Solutions Inc. purchased a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter valued at approximately $81,000. Finally, Farther Finance Advisors LLC raised its stake in shares of BioCryst Pharmaceuticals by 326.8% during the third quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 8,109 shares during the period. Hedge funds and other institutional investors own 85.88% of the company’s stock.

More BioCryst Pharmaceuticals News

Here are the key news stories impacting BioCryst Pharmaceuticals this week:

• Positive Sentiment: Q4 earnings materially beat expectations: GAAP EPS $1.12 vs. consensus $0.07 and revenue $163.3M (up ~209% YoY), signaling improved profitability and top‑line momentum. BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Strong full‑year ORLADEYO revenue: FY‑2025 net sales of $601.8M (+38% y/y) underpin recurring product cash flow and support commercialization progress. BioCryst Reports Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Astria acquisition expands BioCryst’s HAE franchise and prompted an immediate bullish market reaction; management says the deal supports guidance and HAE portfolio scale. BioCryst Boosts HAE Franchise With Astria Acquisition, Guidance
• Neutral Sentiment: Market commentary and valuation pieces are assessing whether the post‑beat rebound leaves BCRX fairly valued; these pieces summarize upside vs. execution risks for investors doing further due diligence. Are BioCryst Pharmaceuticals (BCRX) Shares Offering Value After Recent Price Rebound
• Neutral Sentiment: Management hosted a conference call and published the slide deck and press release; review the materials for guidance details and pipeline commentary that could matter for forward estimates. View Press Release / Slide Deck
• Negative Sentiment: Despite the GAAP beat, reported net margin and return on equity remain slightly negative, and some analysts still forecast a modest FY loss — keep an eye on guidance and margin trajectory. BioCryst Q4 earnings and metrics (MarketBeat)
• Negative Sentiment: Reported short‑interest data for February is inconsistent/odd in public feeds (zero/NaN entries), but any material rise in shorts would be a bearish technical headwind — monitor reliable short‑interest releases for clarity. BioCryst: Q4 Earnings Snapshot

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.